Preliminary results are given of the topical endovesical use of idarubicin for superficial bladder urotheliomas. Its toxicity toward the urothelium is underlined; a fact which strongly compromises its endovesical chemotherapeutic use.
KurtK.H., SchroederF.H., TunnU., AyR., Pavone-MacalusoM., DebruyneF., De PauwM., DalesioO., KateF. and members of the European Organization for Research on Treatment of Cancer, Genitourinary Tract cancer Cooperative Group: Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of European Organization for Research on Treatment of Cancer trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. J. Urol., 132: 258–62, 1984.
2.
LundbeckF., BrunE., FinnerupB., ChristophersenI.S.: Intravesical therapy of non invasive bladder tumours (stage Ta) with doxorubicin: initial treatment results and the long term course. J. Urol., 139: 1212–13, 1988.
3.
Pavone-MacalusoM., CaramiaG.: Adriamycin and daunomycin in the treatment of vesical and prostatic neoplasia, preliminary results. In: CarterS.K.et al. (eds.): International Symposium on Adriamycin. New York, Springer-Verlag, p. 180.
4.
KuthK.H., MrossK., TenkateF. et al.: Phase I-II study of intravesical epirubicin in patients with carcinoma in situ of the bladder. Urol. Prog. Clin. Biol. Res., 350: 41–57, 1990.
5.
NacadaT., AkiyaT., YoshikawaM., KoikeH., KayayamaT.: Intravesical instillation of doxorubicin hydrochloride and its incorporation into bladder tumours. J. Urol., 134: 54–57, 1985.
6.
CarellaA.M., BermanE., MaraoneP.M., GanzinaF.: Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologica, 75: 1–11, 1990.
7.
MrossK., Schultze-SeemannW., BurkK., HossfeldD.K.: Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients bladder tumours. Cancer Chemotherapy Pharmacol., 29: 490–91, 1992.
